Trial Profile
Phase I/II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Isotretinoin; Temozolomide
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 29 Oct 2020 Planned End Date changed from 30 Apr 2024 to 20 Apr 2024.
- 29 Oct 2020 Planned primary completion date changed from 30 Apr 2024 to 20 Apr 2024.
- 13 Dec 2019 Planned End Date changed from 1 Nov 2019 to 30 Apr 2024.